Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543923 | 0.76 | HTR2A (0.47) | HTR2AHTR1ADRD2DRD3CHRM2 | |
| SCHEMBL7542801 | 0.76 | HTR2A (0.47) | HTR2AHTR1ADRD2DRD3CHRM2 | |
| SCHEMBL22837453 | 0.76 | HTR2A (0.47) | HTR2AHTR1ADRD2DRD3CHRM2 | |
| SCHEMBL5034226 | 0.76 | MAP3K14 (0.37) | HTR2AHTR1ADRD2 | |
| SCHEMBL8856952 | 0.75 | DRD2 (0.53) | HTR1ADRD2DRD3CHRM2CHRM1 | |
| SCHEMBL15726642 | 0.72 | AKT1 (0.40) | HTR2AHTR1A | |
| SCHEMBL25003639 | 0.72 | HTR2C (0.31) | HTR2A | |
| SCHEMBL11453907 | 0.72 | HTR2C (0.38) | HTR2AHTR1A | |
| SCHEMBL20478471 | 0.71 | CHRM2 (0.45) | HTR2AHTR1ADRD2DRD3CHRM2 | |
| SCHEMBL3163101 | 0.70 | HTR2A (0.43) | HTR2AHTR1ADRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326718-B2 | 8-Substituted imidazopyridines | ALTANA PHARMA AG (DE) | 2008-02-05 | — | — | US | disclosed |
| US-20060100234-A1 | 8-Substituted imidazopyridines | ALTANA PHARMA AG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100234-A1 | 8-Substituted imidazopyridines | VIP, GIPR, SI | HTR2A 1207/4885HTR1A 1484/4885DRD2 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.